AI-Based Prognostic Assay Validation for Early Breast Cancer
Summary
ClinicalTrials.gov registered NCT07541703, an observational study by Spotlight Medical and the Austrian Breast Colorectal Cancer Study Group (ABCSG) validating a locked AI-based prognostic assay in ER-positive/HER2-negative early breast cancer patients. The blinded retrospective study will use digitized H&E slides from ABCSG-8 with extended follow-up from ABCSG-16 to link assay outputs to clinical outcomes.
What changed
This ClinicalTrials.gov registration documents a new observational study to validate a locked AI-based prognostic assay in early breast cancer. The study will evaluate the assay's prognostic performance in ER-positive/HER2-negative patients using digitized histology slides and clinicopathologic variables from the ABCSG-8 trial. For clinical trial sponsors and medical device developers, this registration illustrates a growing pattern of AI-based diagnostic tools undergoing blinded external validation using archived clinical trial cohorts, with implications for regulatory submissions involving companion diagnostics and prognostic assays.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Independent, External, Blinded Retrospective Validation of an AI-based Prognostic Assay in ER-Positive/HER2-Negative Early Breast Cancer
Observational NCT07541703 Kind: OBSERVATIONAL Apr 21, 2026
Abstract
This retrospective observational study evaluates the prognostic performance of a locked Artificial Intelligence (AI)-based assay in patients with Estrogen Receptor (ER)-positive, Human Epidermal Growth Factor Receptor 2 (HER2)-negative early breast cancer (EBC) from Austrian Breast & Colorectal Cancer Study Group (ABCSG)-8, with extended follow-up from ABCSG-16 where available. ABCSG will provide digitized hematoxylin and eosin (H&E) slides and required baseline clinicopathologic variables to Spotlight Medical without outcome data for blinded assay inference. ABCSG will then perform the prespecified statistical analyses linking assay outputs to clinical outcomes.
Conditions: Breast Cancer, Early Breast Cancer, ER-Positive HER2-Negative Breast Cancer
Interventions: Locked AI-based prognostic assay
Parties
Related changes
Get daily alerts for ClinicalTrials.gov Studies
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from NIH.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when ClinicalTrials.gov Studies publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.